Written and maintained by CASRAI Editorial Board
Last updated
Lipopolysaccharide (LPS) is the major glycolipid of the Gram-negative bacterial outer membrane. It has three domains: lipid A (the hydrophobic anchor), a core oligosaccharide and the O antigen. Lipid A is the part that animal cells detect, through the LBP, CD14 and TLR4-MD2 receptor chain. This page maps each domain to its role so you can read LPS, LOS and “endotoxin” correctly in papers and reagent documentation.
Short answer: what is lipopolysaccharide?
Lipopolysaccharide is a molecule in the outer membrane of Gram-negative bacteria. It is built from lipid A, a core oligosaccharide and, in many species, a repeating O antigen. Lipid A is what the host immune receptor TLR4-MD2 recognises, so changes to lipid A change how strongly the immune system responds (Needham and Trent, 2013).
Definition and scope
Needham and Trent state that “LPS is composed of three domains: the lipid A hydrophobic anchor, the core oligosaccharide and the O antigen.” Maeshima and Fernandez describe the same three regions: lipid A, core sugars and an O antigen made of repeating oligosaccharide units, and note that lipid A anchors LPS in the outer membrane.
In everyday usage “LPS” names the molecule, while “endotoxin” is the term used for its biological activity and for the lab-testing context. The two are closely linked: Maeshima and Fernandez refer to lipid A as the endotoxin portion of LPS. For the testing and limits side, see What Is Endotoxin? and LAL endotoxin testing; this page does not repeat them.
Structure: the three domains of LPS
| Domain | Position and composition | What the sources say |
|---|---|---|
| Lipid A | Hydrophobic anchor in the outer membrane; a di-glucosamine backbone with phosphate groups and acyl chains | Reference E. coli lipid A has six acyl chains and two phosphate groups, and is the strongest known TLR4 ligand (Needham and Trent, 2013; Maeshima and Fernandez, 2013) |
| Core oligosaccharide | Sugar region attached to lipid A, divided into an inner and an outer core | Core and O-antigen biosynthesis varies more across Gram-negative species than lipid A does (Needham and Trent, 2013) |
| O antigen | Repeating oligosaccharide units attached to the outer core | Absent in lipooligosaccharide (LOS), where an extended core region replaces it (Needham and Trent, 2013) |
Lipopolysaccharide in Gram-negative bacteria
LPS sits in the outer membrane, with lipid A embedded in the membrane and the sugar domains facing outward. This is why LPS is associated with Gram-negative rather than Gram-positive organisms. For the staining distinction that separates the two groups in the lab, see Gram stain: procedure, reagents and how to read the result.
LPS versus lipooligosaccharide (LOS)
Some bacteria, for example Neisseria species, produce lipooligosaccharide: the repeating O antigen is absent and an extended core region takes its place (Needham and Trent, 2013). Lipid A is still present, so the TLR4 recognition mechanism below applies to the lipid A portion in both cases.
How LPS triggers the immune response
According to Needham and Trent, detection of lipid A by TLR4 begins with LPS-binding protein (LBP) and CD14 binding to LPS, followed by transfer of LPS to the TLR4-MD2 complex. The complex then signals through two adaptor pathways, named for their adaptors: MYD88 and TRIF (also called TICAM1).
- MYD88 pathway: associated with severe reactions to LPS, and with production of pro-inflammatory cytokines such as TNF, IL-6 and IL-12.
- TRIF (MYD88-independent) pathway: follows endocytosis of the TLR4-MD2 complex and is characterised by interferon-β and interferon-inducible proteins; the authors describe it as less inflammatory.
The response can be severe: the same review notes it can result in tissue damage, organ failure and death, especially in sepsis.
Why lipid A structure decides the response
The information that matters most for interpreting experiments is that “LPS” is not one uniform stimulus. Needham and Trent report that unmodified E. coli lipid A, with six acyl chains and two phosphates, is the strongest known TLR4 ligand, and that lipid A modifications can weaken or abolish TLR4 signalling and change the downstream cytokine profile.
| Organism and condition | Lipid A form | Effect on TLR4 (Needham and Trent, 2013) |
|---|---|---|
| E. coli, unmodified | Hexa-acylated, two phosphates | Strongest known TLR4 ligand |
| Yersinia pestis at 37 °C | Tetra-acylated | TLR4 antagonist; believed to let the pathogen proliferate undetected in the bloodstream early in infection |
| Helicobacter pylori (surface lipid A) | Tetra-acylated, lacking phosphate groups | Displayed on the bacterial surface in place of the hexa-acylated form it synthesises |
Maeshima and Fernandez add that most of what is known about lipid A recognition by TLR4-MD-2 on animal cells comes from studies using hexa-acylated E. coli lipid A, a strong TLR4 agonist. Results from that reference LPS should therefore not be assumed to transfer to LPS from other species.
Where it matters for labs
- Reading the literature: E. coli LPS is the standard model for TLR4 studies (Maeshima and Fernandez, 2013), so conclusions are specific to that lipid A structure.
- Cell-stimulation models: because the response runs through LBP, CD14 and TLR4-MD2 and splits into MYD88 and TRIF outputs, the readout (for example TNF or IL-6 versus interferon-β) reflects which arm was engaged. See monocyte to macrophage differentiation for a related cell-model context.
- Contamination and testing: LPS from Gram-negative bacteria is the target of endotoxin testing; methods and limits are covered in the LAL endotoxin testing guide.
Handling, storage and working-concentration information for a specific LPS reagent comes from the manufacturer’s own product documentation for that lot and preparation, not from this overview.
Common misunderstandings
- “LPS and endotoxin are different chemicals.” Not in practice: the terms overlap, with lipid A described as the endotoxin portion of LPS. The words differ by context (molecule versus activity/testing).
- “All LPS activates TLR4 equally.” No: tetra-acylated or modified lipid A can be a weaker agonist or an antagonist.
- “All Gram-negative LPS has an O antigen.” No: LOS lacks it.
FAQ
What is LPS endotoxin?
LPS is the full outer-membrane molecule; endotoxin is the term used for its biologically active lipid A portion and for what LAL-type tests detect. Maeshima and Fernandez describe lipid A as “endotoxin” within LPS.
How does LPS work?
LPS is bound by LBP and CD14, passed to the TLR4-MD2 complex, and signals through MYD88 and TRIF adaptor pathways, producing pro-inflammatory cytokines and interferon-related responses.
Can you give me some examples of endotoxins?
In this context, the lipid A-containing LPS of Gram-negative bacteria such as E. coli is the standard example. Variants include Y. pestis (tetra-acylated at 37 °C) and H. pylori; Neisseria species make LOS.
How does LPS trigger the immune response?
Through lipid A recognition by TLR4-MD2 after LBP and CD14 binding, as set out in the section above.
Sources
- Needham BD, Trent MS. Fortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis. Nature Reviews Microbiology, 2013. doi:10.1038/nrmicro3047. PMC6913092 (full text read 2026-11-07).
- Maeshima N, Fernandez RC. Recognition of lipid A variants by the TLR4-MD-2 receptor complex. Frontiers in Cellular and Infection Microbiology, 2013;3:3. doi:10.3389/fcimb.2013.00003. PMC3569842 (full text read 2026-11-07).
This page is general educational information, not medical advice.
